Elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison

Aim: Despite the availability of novel treatment options for patients with triple-class exposed/refractory multiplemyeloma , there is a lack of consensus on the optimal regimen. A previous unanchored matchingadjusted indirect comparison (MAIC) of the MagnetisMM-3 (NCT04649359) and LocoMMotion (NCT...

Descrición completa

Detalles Bibliográficos

Principais autores:	Isha Mol, Yannan Hu, Thomas W LeBlanc, Joseph C Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Isabel Perez Cruz, Patrick Hlavacek
Formato:	Artigo
Idioma:	Inglês
Publicado:	Becaris Publishing Limited 2025-04-01
Series:	Journal of Comparative Effectiveness Research
Assuntos:	elranatamab locommotion magnetismm-3 matching-adjusted indirect comparison physician’s choice of treatment triple-class exposed/refractory multiple myeloma
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!